- 4th-generation TIMS XR cell with even greater dynamic range
can identify more than 100k unique peptides with 60 min gradients
at one microgram protein loads, with high-confidence at 1% FDR and
without antigen cross-reactivity
- Increased dynamic range plus new 14-bit digitizer offer
excellent quantitation with <5% protein CVs for many proteins in
three-proteome mixture
- Co-distribution for CellenONE pico-dispenser for single cell
proteomics (SCP)
- New PaSER™ real-time data streaming and intelligent
acquisition control
- timsTOF Pro 2 system revolutionizes 4D Metabolomics together
with pioneering partners in small molecule biomarker
discovery
At the 70th ASMS meeting, Bruker Corporation (Nasdaq: BRKR)
today announced the further evolution of the revolutionary 4D
Multiomics timsTOF platform with the launch of the new timsTOF HT
system. The timsTOF HT includes a novel 4th-generation TIMS
(trapped ion mobility separation) XR cell and 14bit digitizer for
even greater dynamic range, enhanced peptide coverage and more
accurate quantitation, particularly in unbiased 4D plasma and
tissue proteomics and epiproteomics.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220606005373/en/
timsTOF HT instrument (Photo: Business
Wire)
These advances are achieved without compromising the ultra-high
sensitivity and extreme robustness for high-throughput proteomics,
e.g., at 50 samples per day (SPD) or up to 200 SPD, or the high
scientific confidence of better than 1% peptide and protein FDRs
(false discovery rates), avoiding inherent antigen cross-reactivity
in targeted immune-recognition methods. The timsTOF HT instrument
can identify over 100k unique tryptic peptides in 60min gradients
with accurate quantification of better than 5% CVs for many protein
groups in low microgram quantities of a three-proteome mixture,
using the dia-PASEF technique. The timsTOF HT also is optimized for
high-throughput, deep and unbiased plasma proteomics and liquid
biopsy biomarker research.
Professor Florian Meier from the University of Jena said: “Our
ongoing collaboration with Bruker to stream-line tissue analysis is
a key area in clinical proteomics, yet extremely challenging as
tissue sections and biopsies comprise very heterogenous cell
populations. The dia-PASEF acquisition mode on the timsTOF HT
instrument quantifies proteins across a large dynamic range even in
notoriously difficult samples, such as cardiac tissue, without
sacrificing throughput or sensitivity.”
Dr. Bruce Wilcox, Vice President of Proteomics at PrognomiQ
Inc., uses the Seer Proteograph and the timsTOF Pro 2 for deep,
unbiased plasma proteomics in the discovery of biomarkers in a
pancreatic cancer study. Dr. Wilcox stated: “We detected 3822
protein groups across all 5 Seer nanoparticles for the 193
pancreatic cancer and healthy subject samples. Some 2933 protein
groups were identified in at least 25% of the patient samples,
using our several timsTOF systems.”
At ASMS, Bruker also announced that its timsTOF SCP system with
extreme sensitivity is now also available via a co-distribution
agreement with Scienion, together with the CellenONE F1.4
single-cell pico-dispenser and the new ProteoChip™, as a single
vendor solution for unbiased, label-free single cell proteomics
(SCP).
Dr. Holger Eickhoff, CEO and founder of Scienion GmbH, a BICO
company, commented: “We are pleased to offer this complete SCP
solution together with Bruker. Through our expanded partnership we
can even better address the needs of the single cell proteomics
community by combining the expertise of our SCP teams for
accelerated research solutions development in single cell
proteomics.”
PaSERTM with LFQ and Intelligent Acquisition Mode
At ASMS, Bruker demonstrated PaSER’s real-time data streams and
feedback loops for intelligent acquisition processes: developed in
collaboration with the Yates Lab at Scripps, users can impute
acquisition parameters ‘on-the-fly’ based on PaSER’s real-time
decision making for PTM targeting, retention time alignment, and
dynamic inclusion and exclusion. This creates a smarter instrument
for scheduling unseen candidates and deeper analysis.
Professor Alain van Gool, Head of the Translational Metabolic
Laboratory at the Radboud university medical center in Nijmegen,
NL, said: “We use mass spectrometry for discovery of translational
biomarkers in personalized diagnostics in inherited metabolic
disorders, where we focus on expression and glycosylation of
protein biomarkers, and have implemented diagnostic assays. We
innovate these workflows using two timsTOFs that have proven to be
fast and reliable, supported by PaSER for real-time processing,
(glyco)peptide identification and adjustment of instrument
parameters on-the-fly. We are excited to collaborate with Bruker
within our joint Center for Translational Omics on the development
of feedback-based intelligent acquisition modes for glycoproteomics
in clinical applications.”
PaSER version 2023 now includes real-time label-free
quantitation (LFQ) for dda-PASEF, where ‘run and done’ quantitative
results are available shortly after large sample cohorts have been
acquired. PaSER 2023 also incorporates TIMS DIA-NN 1.1 for
dia-PASEF.
Transforming high-throughput and high-confidence discovery 4D
Metabolomics
The high sensitivity timsTOF Pro 2 system assists pioneering
small molecule biomarker discovery partners in revolutionizing
metabolomics at unprecedented scale. New workflows for the
discovery of biomarkers to accelerate drug discovery and novel
natural products exploit the robustness, speed and confidence of
the timsTOF platform in 4D metabolomics.
Sapient Bioanalytics LLC accelerates drug discovery by
uncovering pathways associated with disease mechanism, progression
and patient response by using population-level data to identify
sensitive biomarkers in ultra-high throughput.
Mo Jain, MD/PhD, Founder and CEO of Sapient, explained:
“Sapient’s proprietary rapid LC-MS systems allow to measure
thousands of molecules, including uncharacterized compounds in
samples such as blood. Our six next-gen timsTOF Pro 2 systems allow
us to measure more than 11,000 small molecule biomarkers per
bio-sample in 43 seconds. These systems provide unmatched capacity
to measure over 10,000 bio-samples per day.”
Dr. Viswa Colluru, CEO and Founder of Enveda Biosciences, uses
timsTOF Pro 2 systems to discover new compounds in nature’s
chemistry at an extraordinary pace. He said: “The trapped
ion-mobility collision cross-section (CCS) data provided by
Bruker’s timsTOF provides unprecedented 4D resolution of the many
isomers in the natural world, enabling us to find novel therapeutic
compounds in complex mixtures. The timsTOF Pro 2 combines
cutting-edge virtually lossless ion-mobility technology with fast
high-resolution TOF detection. This combination helps us profile
the natural world at scale and industrialize applications in drug
discovery. Bruker’s commitment to innovation and customers makes
them a great partner. We are excited to continue to redefine the
boundaries of metabolomics with them.”
OligoQuestTM enhanced RNA and Oligonucleotide
characterization software
Bruker’s OligoQuest software offers enhanced RNA and
oligonucleotide characterization for antisense research, RNA
therapeutics, confirmation of guide RNA sequences for CRISPR, and
other gene editing techniques. By exploiting the high isotopic
fidelity and mass accuracy of Bruker’s maXis II and timsTOF
platforms, OligoQuest enables identity confirmation by intact mass
and MS2 analysis. Customers are using OligoQuest for confirmation
of modified RNA sequences and base exchanges in isomeric
oligonucleotides. OligoQuest fills the gap in RNA and
oligonucleotide data analysis with tested algorithms, and also
allowing customers to use their own oligonucleotide “alphabet” for
standard or customized modifications.
Dr. Ingo R�hl, Managing Director Operations, Axolabs GmbH in
Kulmbach, Germany, said: “Isomeric Oligos can be analyzed with
OligoQuest software allowing to identify base exchanges. Already
the first version has been included in our day-to-day
workflows.”
Dr. Michael Greig, Director of BioPharma for Bruker Daltonics,
added: “Axolabs was one of the first companies to focus on RNAi
therapeutics since 2000. Getting their validation for OligoQuest
during the beta-testing phase was important, as we could address
the critical needs of this important class of biologics in a
meaningful manner.”
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. Please visit www.bruker.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220606005373/en/
Media Petra Scheffer Bruker Daltonics Marketing
Communications T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com
Investor Relations Justin Ward Sr. Director Investor
Relations & Corp Development T: +1 (978) 663–3660, ext. 1479 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024